Cover Image
市場調查報告書

市場進入的課題:乾癬 (美國)

Market Access Impact (US) [PsO]

出版商 FirstWord 商品編碼 358481
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的課題:乾癬 (美國) Market Access Impact (US) [PsO]
出版日期: 2017年03月01日 內容資訊: 英文
簡介

本報告提供100名美國的皮膚科醫生的乾癬治療藥的處方趨勢調查,關於處方集、償付、價格等,進入美國市場的障礙及影響因素,主要8品牌比較分析、個別分析。

調查課題

  • 市場進入的各種障礙
    • 醫生最大量開立處方的品牌為何?
    • 受到各種障礙影響的處方箋數是多少?
    • 哪個障礙影響最大?
  • 障礙對各品牌的影響
    • 開立各品牌處方的醫生數是多少?未開立處方但打算考慮數是多少?
    • 不開立處方的理由為何?其替代處方之物為何?
    • 各品牌的市場佔有率是多少?

調查對象

  • Cosentyx (secukinumab:Novartis)
  • Enbrel (Etanercept:Amgen)
  • Humira (Adalimumab:AbbVie)
  • Inflectra (Infliximabdyyb:Pfizer)
  • Otezla (apremilast:Celgene)
  • Remicade (Infliximab:Janssen Biotech)
  • Stelara (Ustekinumab:Janssen Biotech)
  • Taltz (ixekizumab:Eli Lilly)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Top brand takes a big lead thanks to market barriers

In the US, market barriers are having a major impact on the brands used to treat psoriasis-affecting more than a third of all prescriptions and helping some brands stay ahead of rivals. Eliminating barriers would narrow the top brand's sizeable lead, and send the third place brand toppling all the way down to sixth place.

Find whether barriers are holding your brand back, and what you can do about it, in Market Access Impact: Psoriasis (US) .

Based on a survey of 100 dermatologists, the report covers 8 major therapies from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Novartis, and Pfizer. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Market barriers have a big impact: They affect more than one third of psoriasis prescriptions in the US. Cost and market access barriers have by far the biggest impact.
  • Barriers widen the top brand's lead: A net share increase of more than seven percent keeps the leading brand comfortably ahead, but it would continue to lead even if barriers didn't exist.
  • Three brands see significant losses because of barriers: Each of them sees a net market share loss of between 3 and almost 6 percent.
  • Barriers are propping up the third-place brand: Without them, this brand would drop into the bottom three, and two lower-ranked brands would overtake it.
  • Most brands are widely prescribed: 65 to 90 percent of surveyed doctors prescribe the top six brands, while fewer than ten percent of them prescribe the last place brand.
  • “Other” brands benefit too: In aggregate, brands not surveyed see the second largest barrier-related gain, but even without barriers they would still rank ahead of most surveyed brands.

Insight into 8 Major Psoriasis Drugs

  • Cosentyx (secukinumab; Novartis)
  • Enbrel (etanercept; Amgen)
  • Humira (adalimumab; AbbVie)
  • Inflectra (infliximab-dyyb; Pfizer)
  • Otezla (apremilast; Celgene)
  • Remicade (infliximab; Janssen Biotech)
  • Stelara (ustekinumab; Janssen Biotech)
  • Taltz (ixekizumab; Eli Lilly)

Exploring Market Access Barriers

Market Access Impact: Psoriasis (US) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based dermatologists, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with psoriasis in total in the last month

We conducted the survey between February 1st and 7th, 2017.

Table of Contents

  • >1. What are market barriers?
  • >2. About this report
  • >3. About the survey
  • >4. Brands included in the survey
  • >5. Executive summary
Back to Top